statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	411
CN - Cina	261
SG - Singapore	239
HK - Hong Kong	70
BR - Brasile	67
GB - Regno Unito	41
KR - Corea	36
RU - Federazione Russa	26
SE - Svezia	26
DE - Germania	21
VN - Vietnam	21
FI - Finlandia	15
LT - Lituania	13
IT - Italia	10
NL - Olanda	6
AR - Argentina	5
ZA - Sudafrica	5
CA - Canada	4
IE - Irlanda	4
IL - Israele	3
IQ - Iraq	3
JP - Giappone	3
AL - Albania	2
IN - India	2
LA - Repubblica Popolare Democratica del Laos	2
PA - Panama	2
PK - Pakistan	2
PL - Polonia	2
PT - Portogallo	2
AM - Armenia	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BD - Bangladesh	1
BO - Bolivia	1
CR - Costa Rica	1
DO - Repubblica Dominicana	1
IS - Islanda	1
LV - Lettonia	1
MX - Messico	1
NI - Nicaragua	1
NP - Nepal	1
PE - Perù	1
PH - Filippine	1
PY - Paraguay	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TR - Turchia	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.325

Nome	#
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients	126
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myeloid leukemia cells	126
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia	123
A role of PI-PLCb1 in G1/S transition in human erythroleukemia k562 cells	123
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes	113
Involvement of nuclear PLC{beta}1 in lamin B1 phosphorylation and G2/M cell cycle progression	112
Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines	105
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation	102
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS	101
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients	100
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-ami ne (A443654) in T-cell acute lymphoblastic leukemia	98
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside	97
Totale	1.326

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	89	0	0	0	4	9	20	1	14	16	3	8	14
2023/2024	113	3	5	6	21	17	11	21	2	5	0	15	7
2024/2025	586	10	3	0	37	109	87	15	30	91	15	98	91
2025/2026	538	85	87	122	106	110	28	0	0	0	0	0	0
Totale													1.326